7月份对于Novotech在韩国的发展意义非同凡响。在13个国家开展业务的澳大利亚合同研究组织(CRO)发布了两项公告,旨在进一步扩大其在亚太地区热门的CRO市场之一的影响力。7月19日,Novotech宣布,他们在韩国成立了一个新的研究中心管理组织(SMO)。7月26日,公司宣布与韩国SCI-临床试验中心脊髓损伤协会(SCIC)及其代表医院--延世大学医疗院世福兰斯医院签署了一份谅解备忘录(MOU)。
Featured media on Novotech’s leadership and impact.
Expert insights and real-world perspectives.
In-depth perspectives on forces shaping clinical research.
Tracking science and trends across therapeutic areas.
Hear from experts shaping clinical development.
Conversations with leaders shaping drug development.
A global CRO and scientific partner advancing drug development.
Our impact extends beyond trials, shaping healthier futures worldwide.
A collaborative, science-driven approach.
Recognized for excellence across the industry.
Decades of clinical and scientific leadership.
A global clinical research leader with an award-winning culture.
A culture that empowers growth, innovation, and impact.
Explore career opportunities at Novotech.
Benefits and recognition that support your success.
Experts collaborating to advance clinical research.
A commitment to your growth and development.
Start your career in clinical research with Novotech.
7月份对于Novotech在韩国的发展意义非同凡响。在13个国家开展业务的澳大利亚合同研究组织(CRO)发布了两项公告,旨在进一步扩大其在亚太地区热门的CRO市场之一的影响力。7月19日,Novotech宣布,他们在韩国成立了一个新的研究中心管理组织(SMO)。7月26日,公司宣布与韩国SCI-临床试验中心脊髓损伤协会(SCIC)及其代表医院--延世大学医疗院世福兰斯医院签署了一份谅解备忘录(MOU)。